Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQPV7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $10,484.64 to DMS Pharmaceutical Group Inc. for Xolair 300 mg/2 ml autoinjector units on December 5, 2025. This delivery order, designated as a firm fixed-price contract with no set-aside provisions, is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The contract, awarded on November 13, 2025, carries a $500 million ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical regional pharmaceutical supplier for the Department of Defense's global military healthcare operations.
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, has demonstrated substantial federal contracting capability through numerous delivery orders for diverse pharmaceutical products including branded and generic medications, biologics, vaccines, and specialty pharmaceuticals. The company's performance across multiple product categories and therapeutic areas, combined with its established presence in the federal pharmaceutical supply chain since 2001, supports its role as a PPV-G GEN V prime vendor. This delivery order for Xolair—a biologic immunosuppressant indicated for asthma and other conditions—reflects routine procurement activity under the established contract framework to support recurring medical supply needs across Department of Defense healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FQPV7?
SPE2DR26FQPV7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FQPV7 worth?
The government has obligated $10,485 on SPE2DR26FQPV7.
Is contract SPE2DR26FQPV7 an order under another contract?
Yes. SPE2DR26FQPV7 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQPV7 competed?
The extent of competition for SPE2DR26FQPV7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award